

## **SYMBICORT Price Adjustment Rebate (“PAR”) FAQs**

### **Q: Are all customers eligible to participate in the PAR?**

A: All customers who purchase SYMBICORT during the defined eligibility period (12/20/23 – 12/31/23) are eligible for the PAR, except for customers which have been previously communicated as exceptions to this process.

### **Q: Are all SYMBICORT NDCs in scope for the PAR?**

A: The Hospital Unit Dose NDCs (00186-0372-28 & 00186-0370-28) are NOT eligible for the PAR. NDCs 00186-0372-20 & 00186-0370-20 are both in scope.

### **Q: Why are the Hospital Unit Dose (“HUD”) NDCs excluded from PAR eligibility?**

A: The HUD NDCs represent a small percentage of the overall SYMBICORT volume and the vast majority of the HUD volume is sold at a contracted price that is ineligible for the rebate.

### **Q: Why are 340B sales and sales at certain AZ contracted prices excluded from PAR eligibility?**

A: 340B pricing and certain AZ contract prices are ineligible due to the discounting already in place.

### **Q: Why are only sales between 12/20/23 – 12/31/23 eligible?**

A: A defined period of sales was necessary to ensure consistency across customers. The period selected is intended to mitigate the risk of AZ paying rebates on units that were dispensed prior to the effective date of the WAC decrease, and therefore are no longer in inventory.

### **Q: How will SYMBICORT orders be handled? Are those volumes rebate eligible?**

A: The definition of “sales” for the PAR program includes any orders that have been taken and committed to by the distributor during the eligibility period of 12/20/23 – 12/31/23.

### **Q: Do I need to do take any steps to participate in the PAR program?**

A: No, distributors will provide AstraZeneca with a report of all SYMBICORT sales during the eligibility period of 12/20/23 – 12/31/23. The PAR will be paid, via the distributors on all eligible sales not later than 3/15/24.

**Q: Can I just return my SYMBICORT inventory and repurchase at the new WAC?**

A: A Symbicort specific exception to the AstraZeneca's Expired Return Goods (ERG) Policy will be implemented. Future ERG claims for product sold prior to the effective date of a new lower Price will be valued and credited at the new lower price effective January 1, 2024 assuming all other terms of the AstraZeneca Return Good Policy have been met.